Join Growin Stock Community!

Coya therapeutics, inc.COYA.US Overview

US StockHealthcare
(No presentation for COYA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

COYA AI Insights

COYA Overall Performance

COYA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

COYA Recent Performance

-5.14%

Coya therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

COYA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

COYA Key Information

COYA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

COYA Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Price of COYA

COYA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

COYA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.11
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
26.03
PB Ratio
3.82
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-462.25%
Revenue Growth (YoY)
-58.26%
Profit Growth (YoY)
-58.26%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.11
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
26.03
PB Ratio
3.82
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-462.25%
Revenue Growth (YoY)
-58.26%
Profit Growth (YoY)
-58.26%
3-Year Revenue Growth
-%
3-Year Profit Growth
25.99%

  • When is COYA's latest earnings report released?

    The most recent financial report for Coya therapeutics, inc. (COYA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating COYA's short-term business performance and financial health. For the latest updates on COYA's earnings releases, visit this page regularly.

  • What is the operating profit of COYA?

    According to the latest financial report, Coya therapeutics, inc. (COYA) reported an Operating Profit of -2.43M with an Operating Margin of -68.26% this period, representing a growth of 45.33% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is COYA's revenue growth?

    In the latest financial report, Coya therapeutics, inc. (COYA) announced revenue of 3.56M, with a Year-Over-Year growth rate of 0%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does COYA have?

    At the end of the period, Coya therapeutics, inc. (COYA) held Total Cash and Cash Equivalents of 28.13M, accounting for 0.88 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does COYA go with three margins increasing?

    In the latest report, Coya therapeutics, inc. (COYA) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -68.26%%, and net margin of -59.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess COYA's profit trajectory and future growth potential.

  • Is COYA's EPS continuing to grow?

    According to the past four quarterly reports, Coya therapeutics, inc. (COYA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.13. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of COYA?

    Coya therapeutics, inc. (COYA)'s Free Cash Flow (FCF) for the period is -1.13M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 79.3% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.